Homage to the titans of Chinese investigation and the race for lung cancer curability
Preface

Homage to the titans of Chinese investigation and the race for lung cancer curability

Cancer medicine has evolved in recent years thanks to advances in cancer biology, allowing many dedicated scientists and medical oncologists to thoroughly investigate the inner core of cancer cells. The initiative of JTD to gather some of the most prominent Chinese researchers in the field of lung cancer is certainly inspiring for members of the scientific community, especially those dedicated to lung cancer. The selection of Chinese scholars is not arbitrary since all epitomize the main virtues of researchers: full motivation, curiosity, determination and ceaseless work. The readers will find a cornucopia of information on the successes of different Chinese careers and an immense fountain of information and inspiration. Certainly, such salient investigators’ interviews provide a spearhead for further investigators in the complex field of cancer. When reading the interviews, we find many commonalities in research, for example, inflammation and cancer, and can grasp the genetic liaison of cancer within many different disorders, such as aging, diabetes and cardiovascular diseases.

Today we face a new burden, the abundance of generated information and how to translate this information from bench to bed. The editors of AME have performed amazing work conducting these interviews and have selected some of the most relevant talents. After reading the interviews, we recognize these researchers as the titans and caregivers in science and medicine.

The fast advance in medicine is only possible by such dedicated investigators and their groups. China is surfacing as one of the most prominent regions in facilitating this advance with its understanding of the complexities of cancer and, importantly, how these advances can provide new forms of patient treatment, mainly lung cancer patients, with new tangible evidence for better therapies and, ultimately, fulfilling the need to provide new modalities of management, that will eventually lead to curability.


Acknowledgements

None.

Rafael Rosell, MD

Director, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital;
Associate Professor of Medicine, Autonomous University of Barcelona (UAB), Campus Can Ruti, Badalona 08916, Barcelona, Spain.
(Email: rrosell@iconcologia.net)

doi: 10.21037/jtd.2017.09.145

Conflicts of Interest: The author has no conflicts of interest to declare.

Cite this article as: Rosell R. Homage to the titans of Chinese investigation and the race for lung cancer curability. J Thorac Dis 2017;9(Suppl 11):S1150. doi: 10.21037/jtd.2017.09.145